"Sulindac" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
| Descriptor ID |
D013467
|
| MeSH Number(s) |
D02.455.426.559.847.486.875 D04.615.486.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulindac".
Below are MeSH descriptors whose meaning is more specific than "Sulindac".
This graph shows the total number of publications written about "Sulindac" by people in this website by year, and whether "Sulindac" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 3 | 4 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 1 | 5 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulindac" by people in Profiles.
-
Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial. Dis Colon Rectum. 2022 Apr 01; 65(4):536-545.
-
Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prev Res (Phila). 2021 09; 14(9):851-862.
-
Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer. 2020 Sep 10; 20(1):871.
-
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. N Engl J Med. 2020 09 10; 383(11):1028-1039.
-
Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets? Cancer Prev Res (Phila). 2018 01; 11(1):1-3.
-
Chemoprevention of familial adenomatous polyposis. Fam Cancer. 2016 07; 15(3):467-75.
-
Chemoprevention of hereditary colon cancers: time for new strategies. Nat Rev Gastroenterol Hepatol. 2016 06; 13(6):352-61.
-
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA. 2016 Mar 22-29; 315(12):1266-75.
-
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3289-98.
-
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol. 2012 Nov; 48(11):1136-45.